Signatera looks deeper
San Antonio Breast Cancer Symposium
(SABCS) 2020 Virtual Meeting
Personalized tumor-informed test for actionable intelligence in breast cancer
Explore our two presentations at the 2020 San Antonio Breast Cancer Symposium (SABCS) virtual conference and access additional content below. The two posters highlight the unique applications of Signatera to detect recurrence using circulating-tumor DNA (ctDNA).
See our presentations from SABCS
Oral Presentation
Unique applications of Signatera to detect recurrence using circulating-tumor DNA (ctDNA)
Personalized ctDNA as a predictive biomarker in high-risk early stage breast cancer (EBC) treated with neoadjuvant chemotherapy (NAC) with or without pembrolizumab (P)
Spotlight Poster Discussion 9
Read full publication of data originally presented at SABC in 2019
PD9-02
Mark Magbanua, PhD
University of California San Francisco
Unique applications of Signatera to detect recurrence using circulating-tumor DNA (ctDNA)
Genomic analysis from the talazparid beyond BRCA clinical trial:
Homologous recombination (HR) deficiancy scores, loss-of-heterozygosity and mutations in non-BRCA 1/2 mutant tumors with other HR mutations
Spotlight Poster Discussion 10
PD10-12
Joshua Gruber, MD
Stanford University Medical Center
Growing Number of Breast Cancer Studies with Signatera
Signatera has been used in clinical trials for over 500 Breast Cancer patients and that number is growing. See our two recently announced Breast Cancer studies:
Dare Study
Prospective Randomized Clinical Trial to Evaluate Palbociclib in Early Stage Breast Cancer Patients Who Test Positive with Signatera
LEADER Study Part 2
Study to use Signatera to test effectiveness of Ribociclib in combination with endocrine therapy versus standard endocrine therapy